OBJECTIVES We investigate the effect of immediate antiretroviral therapy (ART) eligibility on HIV incidence among HIV-uninfected household members. DESIGN Regression discontinuity study arising from a population-based cohort. METHODS Household members of patients seeking care at the Hlabisa HIV Treatment and Care Programme in rural KwaZulu-Natal South Africa between January 2007 and August ...

Inscrutability arguments threaten to reduce interpretationistmetasemantic theories to absurdity. Can we find some way to block the arguments? A highly influential proposal in this regard is David Lewis’ ‘eligibility’ response: some theories are better than others, not because they fit the data better, but because they are framed in terms of more natural properties. The purposes of this paper ar...

BACKGROUND Poor rates of linkage from HIV diagnosis to ART initiation are a major barrier to universal coverage of ART in sub-Saharan Africa, with reasons for failure poorly understood. In the first study of this kind at primary care level, we investigated the pathway to care in the Malawian National Programme, one of the strongest in Africa. METHODS AND FINDINGS A prospective cohort study wa...

The Patient Protection and Affordable Care Act (ACA) 2010 received two major boosts last year with the upholding of most of the law as legal by the Supreme Court, and the re-election of President Barack Obama. As 2013 proceeds, critical parts of the law are being implemented across the United States. At the heart of the ACA is the federal objective of expanding insurance coverage. A substantial...

On June 7, 2021, the U.S. Food and Drug Administration (FDA) approved aducanumab, an amyloid beta-directed monoclonal antibody, as a new treatment for Alzheimer's disease (AD),1 taking advantage of Accelerated Approval program. The aducanumab effect on beta plaques2 was deemed to predict benefits patients and, thus, considered approvable surrogate endpoint. Nevertheless, there are residual unce...